The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Kanjinti

420 milligram(s) Pdr/Conc/Soln for Infus

Amgen Europe B.V.EU/1/18/1281/002

Main Information

Trade NameKanjinti
Active SubstancesTrastuzumab
Strength420 milligram(s)
Dosage FormPdr/Conc/Soln for Infus
Licence HolderAmgen Europe B.V.
Licence NumberEU/1/18/1281/002

Group Information

ATC CodeL01XC Monoclonal antibodies
L01XC03 trastuzumab

Status

Authorised/WithdrawnAuthorised
Licence Issued16/05/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing Status

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back